# Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors

> **NCT00003555** · PHASE1 · COMPLETED · sponsor: **State University of New York - Upstate Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** amifostine trihydrate
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00003555
- **Lead sponsor:** State University of New York - Upstate Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2013-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003555, "Paclitaxel Plus Chemoprotection With Amifostine in Treating Patients With Recurrent or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*